<DOC>
	<DOCNO>NCT02868580</DOCNO>
	<brief_summary>This phase 2a open label , multicentre design study investigate safety Triumeq patient ALS 24 week post treatment . In phase 2a study investigator aim determine whether combination anti-retroviral therapy , Triumeq ( dolutegravir 50mg , abacavir 600mg , lamivudine 300mg ) tolerate safe patient ALS . As secondary outcome , ALSFRS-R , ALSQOL , physical examination , neurophysical parameter respiratory muscle function evaluate . Blood urine sample store possible future analysis viral activity . Subjects screen study sign approve Informed consent document .</brief_summary>
	<brief_title>Safety Tolerability Antiretroviral ( Triumeq ) Patients With Amyotrophic Lateral Sclerosis ( ALS ) .</brief_title>
	<detailed_description>This study multi-centre , open-label longitudinal study investigate safety tolerability combination antiretroviral therapy ( Triumeq ) Motor Neuron Disease ( MND ) /Amyotrophic Lateral Sclerosis ( ALS ) 24 week 40 HIV negative ALS patient . The overall study duration 34 week , 14 day screen , follow 8-week lead-in phase 24-week treatment phase . Outcomes measure 4 , 8 , 12 , 20 24 week . Participants follow 4-weekly interval safety clinical measure . Subjects screen study sign approve Informed consent form . As part 14 day screen phase , subject undertake extensive medical neurological assessment . Following screen phase subject enter 8 week lead-in-phase . During phase , undertake two ALSFRS-R 4 week interval . The ALSFRS-R undertaken subject telephone . At baseline visit , follow lead-in-period , blood urine take safety monitoring also bio-banked possible future measurement Human Endogenous Retroviruses ( HERVs ) . Baseline sign symptom collect . All subject inclusion exclusion criterion check Baseline visit ( Week 0 ) eligible subject start Triumeq . Subjects return centre Weeks 4 , 8 , 16 , 24 7 day last dose investigational product ( early termination ) undertake neurological examination well assessment ALS Functional Rating Scale-Revised ( ALSFRS-R ) , neurophysical index ( NPI ) , force vital capacity ( FVC ) measure handheld spirometer , SNIP test quantitative hand muscle test dynamometry . All subject undertake evaluation hematological biochemical parameter collection blood urine sample bio-banking . A voice record undertaken . At early termination visit , subject undergo ECG Test . At baseline , week 8 , 16 24 early termination visit subject ask complete Columbia Suicide Severity Rating Scale . At screen week 8 end treatment/early termination visit , subject also ask complete ALSFRS-R. SAE 's , AE 's change concomitant medication observe evaluate throughout study . Each study visit 7 day window due date account schedule conflicts/holidays/weekends . Subjects give additional study product account 7- day window .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Subjects must meet follow inclusion criterion eligible participate study : Age 1875 year time screen visit Able provide inform consent comply study procedure Sporadic ALS diagnose probable , laboratorysupported probable definite accord World Federation Neurology El Escorial revise criterion determine neurologist neuromuscular subspecialty training Diagnosis &lt; 24 month date enrolment ( Forced ) Vital capacity least 60 % predict value gender , height age screen visit Must stable dose riluzole least 30 day prior screen visit . Subject establish care neurologist one four specialized ALS clinic involve study maintain clinical care throughout study . Subjects participate clinical registry , exclude protocol participate clinical trial involve additional investigative treatment exposure . A participant exclude following : Dependence mechanical ventilation time screen Gastrostomy time screen Absence Upper Motor Neuron Signs Participation investigational drug trial use investigational drug ( within 12 week prior screen ) Known hypersensitivity dolutegravir , abacavir lamivudine , excipients Presence HLAB*5701 allele screen Presence monogenic cause ALS ( e.g . know mutation SOD1 , expansion c9orf72 etc . ) History positive test positive result screen HIV Subjects positive Hepatitis B screening ( +HBsAg ) , anticipate need Hepatitis C virus ( HCV ) therapy study* ; Women must able become pregnant ( post menopausal &gt; 1 year , surgically sterile , adequate contraception ) breastfeed duration study . Women childbearing potential must negative pregnancy test screen nonlactating Other interventional clinical trial Subject take medication contraindicate Triumeq . Dofetilide ( pilsicainide [ available Japan ] ) prohibit DTG may inhibit renal tubular secretion result increase dofetilide concentration potential toxicity . Presence follow clinical condition time screening : Drug alcohol abuse Unstable medical disease ( unstable angina chronic obstructive pulmonary disease ) , active infectious disease ( Hepatitis B C tuberculosis ) , current malignancy Unstable psychiatric illness define psychosis untreated major depression within 90 day screen visit . This exclusion criterion base prior psychiatric diagnosis unstable determine subject 's treat Psychiatrist Dementia previously diagnose medical practitioner â€¢ Safety Laboratory Criteria screen visit : Alanine aminotransferase ( ALT ) &gt; 5 time upper limit normal ( ULN ) , OR ALT &gt; 3xULN Total bilirubin , lactate , triglyceride , amylase , lipase great 2.0 time upper limit normal Subject creatinine clearance &lt; 50 mL/min via CockroftGault method Subjects moderate severe hepatic impairment ( Class B great ) determine ChildPugh classification ; Absolute neutrophil count &lt; 1 x 109/L Platelet concentration &lt; 100 x 109/L Haemoglobin &lt; 100g/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ALS</keyword>
	<keyword>Antiretroviral Therapy , Triumeq</keyword>
</DOC>